Co-targeting of PIM and PI3K has been attempted in prostate cancer using different combinations of drugs12,19; these studies suggest that co-targeting PIM and PI3K could offer superior clinical outcomes to targeting either alone. This evidence concerns the gene PIM1 and prostate cancer.